GERON CORP Quarterly and Half-Year Results: RYTELO Revenue Rises Year Over Year as Losses Persist

Bottom line

For the three-month reporting period, GERON CORP (ticker GERN, CIK 0000886744) recorded Revenue from Contract with Customer, Excluding Assessed Tax of $57,480,000 USD, against a prior-year quarter figure of $49,036,000 USD — the authorized direction is higher year over year. Operating Income (Loss) was -$12,496,000 USD versus -$12,454,000 USD, with the authorized direction lower year over year and the transition reported as loss to loss. Net Income (Loss) Attributable to Parent was -$16,680,000 USD versus -$16,375,000 USD, also moving lower year over year on a loss-to-loss basis. Earnings Per Share, Diluted was -$0.02 per diluted share USD/SHARES versus -$0.02 per diluted share USD/SHARES, characterized as roughly flat quarter over quarter with a loss-to-loss transition.

For the six-month year-to-date period, Revenue from Contract with Customer, Excluding Assessed Tax was $109,317,000 USD versus $88,639,000 USD, with the authorized direction higher year over year. Operating Income (Loss) was -$12,338,000 USD versus -$29,158,000 USD, characterized as loss to loss with the authorized direction higher. Net Income (Loss) Attributable to Parent was -$20,322,000 USD versus -$36,210,000 USD, also loss to loss with the authorized direction higher. Earnings Per Share, Diluted was -$0.03 per diluted share USD/SHARES versus -$0.05 per diluted share USD/SHARES, again loss to loss but with the authorized direction higher than the prior year.

The filing that anchors this picture is the Form 10-Q covering the three months ended June 30, 2026 and the six months ended June 30, 2026, filed under accession 0000886744-26-000037 for fiscal period period-ended-2026-06-30. The interim period basis of presentation is drawn from Note 1, the company’s product revenue recognition discussion refers to RYTELO, and fair-value hierarchy context relies on Level 1 and Level 2.

None have been transcribed for this section beyond what is summarized above; no narrative drivers of the quarter-to-quarter or year-over-year movements are quoted.

No independent analyst inference has been layered onto these results; only the reported direction labels above are used.

None provided in the quoted filing extract beyond the prior-period comparatives themselves.

UNKNOWN: The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison.

Financial performance

- For GERON CORP's three-month reporting period, the three months ended June 30, 2026, Revenue from Contract with Customer, Excluding Assessed Tax was $57,480,000 USD, an authorized year-over-year increase against the prior-year comparable of $49,036,000 USD for the three months ended June 30, 2025. - For the six-month year-to-date period, the six months ended June 30, 2026, Revenue from Contract with Customer, Excluding Assessed Tax was $109,317,000 USD, an authorized year-over-year increase against the prior-year comparable of $88,639,000 USD for the six months ended June 30, 2025.

S. sales of RYTELO. - Operating Income (Loss) for the three months ended June 30, 2026 was -$12,496,000 USD, a loss, and the authorized year-over-year comparison shows this loss was wider than the prior-year loss of -$12,454,000 USD for the three months ended June 30, 2025.

- Operating Income (Loss) for the six months ended June 30, 2026 was -$12,338,000 USD, a loss, while the prior-year loss for the six months ended June 30, 2025 was -$29,158,000 USD. The authorized direction for the half-year comparison is a narrowing of the loss, although both periods remain loss-making. - Net Income (Loss) Attributable to Parent for the three months ended June 30, 2026 was -$16,680,000 USD, a loss that the authorized comparison describes as wider than the prior-year loss of -$16,375,000 USD for the three months ended June 30, 2025.

- Net Income (Loss) Attributable to Parent for the six months ended June 30, 2026 was -$20,322,000 USD, a loss. Against the prior-year loss of -$36,210,000 USD for the six months ended June 30, 2025, the authorized comparison is a narrowing of the loss, although both windows remain loss-making. 02 per diluted share USD/SHARES for the three months ended June 30, 2025.

03 per diluted share USD/SHARES, a loss. 05 per diluted share USD/SHARES for the six months ended June 30, 2025 is an increase (that is, the per-share loss narrowed). - Together these authorized comparisons describe a pattern in which revenue grows year over year on both windows while the operating loss widens in the quarter and net loss widens in the quarter; over the half-year period both operating loss and net loss narrow, although both remain loss-making.

- The filing evidence does not attribute this change to any single cause. - Accounting context for period-ended-2026-06-30 filed under accession 0000886744-26-000037 is shaped by a few recurring assumptions disclosed in the unaudited condensed consolidated financial statements, covering accrued liabilities, revenue recognition, fair value of marketable securities, inventory valuation, operating leases and related right-of-use assets, lease liabilities, income taxes, and stock-based compensation together with interest expense on the sale of future royalties.

- Inventory positions are linked entirely to the manufacturing of RYTELO, while the available-for-sale securities held in treasury, municipal, commercial-paper and corporate-note form are marked against fair-value measurements that the filing allocates to Level 1 for money-market funds and certificates of deposit, to Level 2 for treasury, municipal, government-sponsored enterprise and corporate-note holdings, and to Level 3 for embedded derivatives and the liability tied to the Royalty Pharma sale-of-future-royalties arrangement discussed further in Note 7.

No transfers occurred between the three fair-value tiers during the periods presented. - The filing's reference to Note 1 confirms that the significant accounting policies used for the three- and six-month periods ending in the current reporting cycle are consistent with those described in the most recent annual Form referenced there, with no identified credit-loss allowances on available-for-sale securities for the current three- and six-month windows because unrealized losses on those securities were attributed to interest-rate movement rather than credit factors.

- Other recent accounting pronouncements, including the FASB ASU addressing Expense Disaggregation Disclosures, are still being evaluated by management and have not been adopted yet, and management does not view other recent FASB pronouncements as having a material impact on the financial statements. S. uptake of RYTELO and on the assumptions built into the Royalty Pharma-related fair-value model, but the filing does not provide forward guidance figures, and peer performance data are not included here.

- The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison.

Operating drivers and segments

S. net product revenue of RYTELO, with all inventory tied to that product's manufacturing. - Reported Revenue from Contract with Customer, Excluding Assessed Tax for the three-month reporting period the three months ended June 30, 2026 ($57,480,000) was higher than the prior-year comparative the three months ended June 30, 2025 ($49,036,000); the authorized direction is increase for both observed windows.

- Reported Revenue for the six-month year-to-date period the six months ended June 30, 2026 ($109,317,000) was higher than the prior-year comparative the six months ended June 30, 2025 ($88,639,000); the authorized direction is increase for both observed windows. - Reported Operating Income (Loss) for the three-month period the three months ended June 30, 2026 (-$12,496,000) was a loss and moved in the worse direction relative to the prior-year comparative the three months ended June 30, 2025 (-$12,454,000), which was also a loss; the authorized transition is loss to loss with a decrease.

- Reported Operating Income (Loss) for the six-month period the six months ended June 30, 2026 (-$12,338,000) was a loss and improved relative to the prior-year comparative the six months ended June 30, 2025 (-$29,158,000), which was also a loss; the authorized transition is loss to loss with an increase. S. net product revenue from RYTELO, noting that, to date, this has been the company's only source of product revenue, with all reported inventory tied to RYTELO manufacturing.

K. and Netherlands entities and intercompany balances eliminated. - Management discusses the implementation of a new FASB pronouncement on expense disaggregation (issued in November of the prior year) that is not yet effective for fiscal years beginning after a later December cut-off and is still being evaluated for its impact on consolidated financial statements.

- Management states that the available-for-sale securities portfolio (treasury, municipal, commercial paper, corporate notes) experienced fair-value changes attributable to interest-rate movements, that no credit-loss allowances were recorded for the three and six months ended in mid-year, and that the company does not intend to sell and is not more likely than not required to sell before recovery of amortized cost. <prose> - Reported revenue from the RYTELO product grew in both observed windows (three-month and six-month) on a year-over-year basis, while reported operating losses moved in opposite directions across the two windows, narrowing for the year-to-date but widening for the quarter.

The filing evidence does not attribute this change to any single cause. - The filing presents no segment breakout beyond the consolidated single segment, with no geographic or therapeutic-area disaggregation disclosed in the cited notes; operating-margin commentary therefore cannot be tied to any sub-unit. The filing evidence contains no peer or industry comparison.

S. product and offers no quantitative volume-versus-price split, leaving gross-to-net drivers undisclosed in the cited evidence. - Management's discussion of accounting policy and fair-value measurement focuses on process rather than outcome: the new expense-disaggregation ASU is still under evaluation, and the unrealized-loss discussion attributes portfolio fair-value movement to interest rates rather than credit risk, with no allowance taken.

- Counter-evidence available in the cited notes is limited to the fair-value hierarchy framework (Levels One, Two, and Three) and the debt-related fair-value determination in the cited debt note, neither of which contradicts the reported revenue or operating-loss movements. - The combined picture is one product, one revenue geography, and two windows of operating-loss change in opposite directions, with management offering qualitative process explanations but no quantified bridge from revenue growth to the divergent operating outcomes.

- Readers who want to compare operating-loss directionality across periods can frame the observed window against the Atlantic Union Bankshares posts higher year-over-year profit on every reported earnings line for both the three-month reporting period and the six-month year-to-date period reference for a contrast in profitability directionality, though no peer-figure overlap is asserted here.

Cash flow and capital

Reported facts

- The cash flow statement for the six-month year-to-date period shows that operations remained a use of cash, with Net Cash Provided by (Used in) Operating Activities of -$78,733,000 USD for the six months ended June 30, 2026, compared with a smaller use of cash of -$75,394,000 USD for the six months ended June 30, 2025. Net Cash Provided by (Used in) Investing Activities was a source of cash in both windows, at $60,151,000 USD for the current period versus $72,754,000 USD in the prior-year comparative. Financing activities supplied cash of $3,809,000 USD for the six months ended June 30, 2026 and $1,347,000 USD for the six months ended June 30, 2025. - The balance sheet at the balance sheet date of June 30, 2026 lists Cash and Cash Equivalents, at Carrying Value of $62,643,000 USD, Accounts Receivable, after Allowance for Credit Loss, Current of $51,640,000 USD, and Accounts Payable, Current of $8,805,000 USD. Long-term Debt, Excluding Current Maturities stood at $120,131,000 USD at the same date.

Management explanations and supporting notes

- The filing discusses the Pharmakon Loan Agreement and describes an amendment that, according to Note 7, extended the Makewhole Date and re-dated the availability of the Tranche B Loan and Tranche C Loan, neither of which were drawn and both of which are no longer available. Proceeds from the Tranche A Loan were used to repay, in full, amounts owed under the Hercules Loan Agreement, which was terminated in connection with the funding. - The fair-value discussion in the filing references Level 1, Level 2 and Level 3 inputs, and states that the liability related to the sale of future royalties is valued based on management's current estimates of future royalties payable to Royalty Pharma, which the filing classifies within Level 3. The filing adds that there were no transfers between the three fair-value levels during the periods presented.

Analyst inference

- Operating cash burn widened year over year, while investing activities shifted toward a larger net inflow and financing inflows increased, a pattern that is consistent with proceeds from the Pharmakon Tranche A Loan being used to retire the Hercules facility and to support working-capital needs. The size of the cash and equivalents balance at the balance sheet date of June 30, 2026 and the level of long-term debt both speak to the post-financing capital structure rather than the pre-financing one. The filing evidence does not attribute this change to any single cause. - With revenue from RYTELO just beginning to scale, accounts receivable remains a small line item relative to cash on the balance sheet, and the long-term debt figure reflects the Pharmakon Term Loan rather than any near-term maturity within the current window. The filing evidence contains no peer or industry comparison.

Counter-evidence and unknowns

- The filing does not break out the maturity profile of the Pharmakon Term Loan or quantify how much of the loan proceeds remain unspent at the balance sheet date of June 30, 2026, so the runway implied by the cash balance cannot be derived from the disclosed data. - No segment-level split of capital expenditures, working-capital movements, or debt repayments is provided for the six months ended June 30, 2026, so any allocation between commercial-launch investment, clinical-program funding, and general corporate purposes is not visible in the evidence. The filing evidence does not disclose segment-level detail for this dimension. - The filing also does not disclose the current-versus-noncurrent split of the royalty liability, the carrying value of marketable securities, or the identity of counterparties beyond Royalty Pharma, so further balance-sheet texture is not available.

Peer and historical context

- Across both reported windows, GERON CORP (GERN, CIK 0000886744) shows the same directional pattern in every line item for which the catalog records a direction: top-line growth paired with deeper operating losses and a wider bottom-line loss, while cash burn moved further into the red. The half-year revenue and operating loss moved in opposing directions (revenue higher, operating loss higher in absolute terms), which on a standalone basis is the textbook profile of a commercial-stage biotech ramping sales ahead of cost coverage.

- The three-month picture versus its prior-year quarter sharpens the read: revenue was higher year over year, while both operating loss and net loss moved in the same loss-to-loss direction that was wider than the year-ago quarter. The half-year net loss also widened against the prior-year half-year, but the diluted per-share line held flat quarter over quarter, suggesting share count expansion may be absorbing some of the per-share impact. - For an outside reader, the half-year cash-flow line (operating cash outflow higher than the prior-year outflow) is the most decision-relevant comparison in this section, because it shows the commercial ramp is not yet self-funding.

Readers who want a cross-issuer contrast can place this pattern beside the recent Atlantic Union Bankshares posts higher year-over-year profit on every reported earnings line for both the three-month reporting period and the six-month year-to-date period write-up, which illustrates the opposite earnings mix. - The reported pattern (revenue up, losses wider) is not unique to this issuer, but the filing itself does not pair those moves with any peer or industry benchmark; The filing evidence contains no peer or industry comparison.

applies here, so the comparison above is limited to the company's own prior periods and cannot be validated against named competitors. - The filing evidence does not attribute this change to any single cause. - The half-year view also contains two positive non-operating comparisons the catalog flags as higher year over year — accretion/amortization on investments and net financing cash inflow — which partially offset the heavier operating burn on a total-cash basis.

Readers should not interpret the wider operating loss as a fully unmitigated deterioration in the issuer's liquidity profile without also weighing those flows. - Segment-level commentary is not available in the filing for the dimensions discussed here; The filing evidence does not disclose segment-level detail for this dimension. means any product-versus-platform split within RYTELO®-driven revenue, referenced via Item 5, cannot be derived from this section's evidence and must wait for a later disclosure.

- Finally, the fair-value hierarchy notes (see Level 1, Level 2, and Level 3) and the Pharmakon debt amendment language (see Note 7) describe balance-sheet mechanics rather than operating performance, so they should not be read as counter-signals to the earnings comparison; they are listed here only to confirm the filing does not introduce a competing operating-data point.

Scenario analysis

The reported picture frames a constructive but still-loss-making operating setup. Revenue from Contract with Customer, Excluding Assessed Tax was $49,036,000 USD for the three months ended June 30, 2025 and $57,480,000 USD for the three months ended June 30, 2026, with the authorized direction between those two periods being higher. Revenue from Contract with Customer, Excluding Assessed Tax was $88,639,000 USD for the six months ended June 30, 2025 and $109,317,000 USD for the six months ended June 30, 2026, with the authorized direction between those two periods being higher. Against that top-line growth, Net Income (Loss) Attributable to Parent was -$16,375,000 USD for the three months ended June 30, 2025 and -$16,680,000 USD for the three months ended June 30, 2026, with the authorized direction being a larger loss and the authorized transition being loss to loss. Net Income (Loss) Attributable to Parent was -$36,210,000 USD for the six months ended June 30, 2025 and -$20,322,000 USD for the six months ended June 30, 2026, with the authorized direction being a smaller loss and the authorized transition being loss to loss. The filing evidence does not attribute this change to any single cause.

A constructive read builds on the year-over-year gain in Revenue from Contract with Customer, Excluding Assessed Tax across both the the three months ended June 30, 2026 versus the three months ended June 30, 2025 comparison and the the six months ended June 30, 2026 versus the six months ended June 30, 2025 comparison. In that frame, the the six months ended June 30, 2026 versus the six months ended June 30, 2025 result for Net Income (Loss) Attributable to Parent moves in the authorized direction of a smaller loss while remaining a loss, and Operating Income (Loss) for the same comparison is in the authorized direction of a smaller loss with the authorized transition loss to loss. The Note 7 on debt — covering the sale-of-future-royalties liability, the termination of the Hercules facility during the period covered by the filing, and the Pharmakon amendment that extended the Makewhole Date — describes financing flexibility rather than revenue traction. The filing evidence does not attribute this change to any single cause.

The cautious read focuses on the bottom line rather than the top line. Net Income (Loss) Attributable to Parent for the three months ended June 30, 2026 versus the three months ended June 30, 2025 is in the authorized direction of a larger loss with the authorized transition loss to loss, even though Revenue from Contract with Customer, Excluding Assessed Tax for that same comparison moves higher. The Pharmakon Loan Agreement cited in Note 7 is secured by substantially all of the company's assets, including intellectual property, and lists customary restrictive covenants and events of default — including a material adverse change or a withdrawal event in respect of RYTELO — which a cautious reader can weigh against the product-line narrative. The same comparison for Operating Income (Loss) is in the authorized direction of a larger loss with the authorized transition loss to loss. The filing evidence does not attribute this change to any single cause.

Risks and what to watch

- Reported facts: Under the Pharmakon Loan Agreement, GERON CORP's obligations are secured by substantially all of its assets, including intellectual property, and certain subsidiaries may be required to guarantee those obligations, pledging substantially all of their assets as well. Interest is due and payable quarterly on the last day of each quarter. The agreement also imposes customary affirmative and restrictive covenants, including obligations to deliver information, maintain insurance, provide notices, and refrain from actions such as selling assets, waiving material agreements, undertaking change-in-control transactions without paying amounts due, incurring additional indebtedness, placing non-permitted liens, paying dividends, or making payments on subordinated indebtedness, each subject to specified exceptions.

- Reported facts: Prepayments of any Term Loan prior to a date in May are subject to a make-whole amount equal to the sum of all interest that would have accrued through that date, and prepayments also carry an additional premium. Term Loans require an upfront payment equal to a portion of the Lenders' total committed amount, payable on each Term Loan's funding date. - Reported facts: The Pharmakon Loan Agreement contains listed events of default that include failure to pay principal, interest, and other amounts when due, breach of covenants, the occurrence of a material adverse change or a withdrawal event in respect of RYTELO, certain attachments and restraints on the credit parties' business, certain insolvency-related events, certain cross-default of third-party indebtedness and royalty revenue contracts, failure to pay certain judgments, material misrepresentations, the loan documents ceasing to create a valid security interest in a material portion of the collateral, certain ERISA events, and the occurrence of a default under any subordination or intercreditor agreement.

The cited note on Debt also discusses the fair value of the liability related to the sale of future royalties. - Management explanations: Management frames the covenant package as customary and tied to specified exceptions and grace, cure, and threshold periods as specified in the Pharmakon Loan Agreement. The intellectual-property pledge is presented as a routine collateral feature rather than as an unusual grant.

- Analyst inference: The combination of broad collateral, intellectual-property encumbrance, restricted-payment and additional-indebtedness covenants, and material-adverse-change plus RYTELO withdrawal-event triggers concentrates several binary risk levers into a single secured facility. Any covenant breach, collateral-insufficiency finding, or a RYTELO withdrawal event could materially change the financing picture in a way that the reported revenue and net income lines would not capture on their own. - Counter-evidence: The covenant package, the make-whole economics, and the default menu are described as standard for this type of facility, and the cited note on Debt describes a separately valued royalty-related liability, which can broaden the financing structure beyond a single loan agreement.

Quarter-to-date revenue of $57,480,000 USD compares against $49,036,000 USD, with the six-month year-to-date period showing $109,317,000 USD against $88,639,000 USD, signaling top-line momentum in both windows even as the net income line remains a loss on a quarter and year-to-date basis at -$16,680,000 USD versus -$16,375,000 USD and -$20,322,000 USD versus -$36,210,000 USD. - Unknowns: Whether any covenant headroom is narrowing, whether the RYTELO withdrawal-event language has been triggered or is currently remote, and whether the royalty-related liability referenced in the cited note on Debt has been remeasured relative to prior disclosures are not addressed by the filing evidence.

The filing evidence does not attribute this change to any single cause.. The filing evidence contains no peer or industry comparison.. The filing evidence does not disclose segment-level detail for this dimension..

- Next period: Watch for any disclosure indicating covenant pressure, a RYTELO withdrawal-event assessment, the make-whole prepayment economics if a refinancing window opens before that May date, and changes in the fair-value disclosure for the royalty-related liability discussed in the cited note on Debt. Readers weighing covenant-sensitive exposures may also want to compare covenant-heavy peers such as the one profiled in Atlantic Union Bankshares posts higher year-over-year profit on every reported earnings line for both the three-month reporting period and the six-month year-to-date period to gauge how standard these packages remain.